应用自体静脉套和脑细胞生长肽对面神经损伤恢复影响的临床研究

目的研究采用自体静脉管套入吻合口并注入脑细胞生长肽的方法,对面神经损伤后功能恢复的影响.方法吻合神经断端后用自体静脉管套入吻合口并注入脑细胞生长肽.分析肌电图和观察表情肌功能恢复,比较两种方法对损伤的面神经功能恢复的影响.结果自体静脉管套入吻合口并注入脑细胞生长肽的方法,比传统方法表情肌功能恢复时间明显缩短,且一期修复比二期修复功能恢复时间明显缩短,差异具有非常显著性意义(P＜0.01).两种方法修复面神经损伤,表情肌功能恢复后检测面神经传导速度差异无显著性意义(P＞0.05).结论自体静脉管套入吻合口并注入脑细胞生长肽的方法是一种比较有前途的面神经修复方法.     

结构蛋白及血管形成因子在体表海绵状静脉畸形中的表达及意义

目的：研究结构蛋白及血管形成因子（VEGF）在体表海绵状静脉畸形（cavernous venous malformation,CVM）中的表达及意义。方法：1996－2000年CVM病理样本25例，取正常中、小型静脉各12例。采用Envision法免疫组化染色观察Ⅳ型胶原、纤维连接蛋白（Fn）、层粘连蛋白（Ln）及VEGF、血管生成素－1（Ang-1）等血管形成因子的表达，半定量分析结果。结果：Ⅳ型胶原、Fn和Ln在海绵状静脉畸形与中、小静脉中的分类似，但表达量明显较少。畸形组织和小静脉VEGF表达明显强于中型静脉，小静脉Ang-1表达明显强于静脉畸形和中型静脉。结论：Ln及VEGF表达变化可能是海绵状静脉畸形形成发展的重要因素。Ang-1表达减少可能参与海绵状静脉畸形的血管塑形障碍的发生。     

The human type II collagen gene (COL2A1) assigned to 12q14.3

A cosmid clone containing the entire human type II α1 collagen gene ( COL2A1 ) was used as probe in the Southern analysis of DNA from a panel of human/hamster somatic cell hybrids containing different portions of human chromosome 12. Two of the hybrids exhibited a similar terminal deletion q14.3→qter, but one was positive for the gene while the other was negative. Therefore, the gene must reside in the region q14.3.     

Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection

An enzyme immunoassay (EIA) for serum antibodies to human immunodeficiency virus type 1 (HIV-1), based on the synthetic pentadecapeptide SGKLICT-TAVPWNAS, a segment of the transmembrane glycoprotein (gp41) of the virus, was developed and tested for sensitivity and specificity. Sera of 152 individuals at various stages of HIV-1 infection, including two prospectively and six retrospectively studied patients exposed to HIV-1 but seronegative on initial testing in whole-virus EIA and immunoblotting, were screened with the gp41 peptide antibody EIA. The reference population consisted of 1,000 healthy HIV-1 antibody-negative blood donors. In addition, five individuals with antibodies to HIV-2 were studied. Antibodies to the synthetic peptide were detected in 100% of those with asymptomatic infection. Only one patient with LAS failed to react in the peptide EIA. Patients with HIV-2 infection did not react in this test. The peptide antibodies appeared rapidly after infection, were detectable at the time when seroconversion was observed by immunoblotting, and preceded reactivity in whole-virus EIA. Sera of seven patients with verified HIV-1 infection did not react with gp41 in immunoblotting, although antibodies were readily detectable in the gp41 peptide EIA.     

Semen analysis and treatment risk factors in long-term survivors of childhood cancer

The objective of this study was to compare semen quality (sperm density, progressive motility and spermia) between long-term childhood cancer survivors and a control group of males. The second objective was to correlate the semen analysis of the survivors with cancer treatment and endocrine status. The semen quality of 143 survivors (median age, 23.6 years) was compared to 200 men (median age, 27.9 years) who had not been diagnosed with cancer. The cancer-related risk factors and gonadotrophin levels were compared. Overall, 65% of the survivors had abnormal semen analysis compared to 26.5% of the controls (p < 0.0001). Survivors with nonaspermia had lower sperm density than the controls (p < 0.001). Other observed correlations were not significant. Survivors who were treated with alkylating agents were more likely to have abnormal semen analysis (p < 0.008). Follicle-stimulating hormone and luteinising hormone levels were significantly elevated (p < 0.0001) in survivors with abnormal semen analysis. The semen quality parameters, except for low sperm density, did not differ in survivors with nonaspermia compared to the controls. The risk factors included treatment with alkylating agents. Elevated gonadotrophin levels correlated with abnormal semen analysis. All cancer survivors should be made aware of the possibility of suffering from cancer treatment-related infertility.     

Structural volumetry in NPH diagnostics and treatment—future or dead end?

Neurosurgical Review - To assess automated volumetric analysis as a potential presurgical diagnostic tool or as a method to potentially shed light on normal pressure hydrocephalus (NPH)...     

Concentrating stroke care provision in the Czech Republic: The establishment of Stroke Centres in 2011 has led to improved outcomes

This article describes policy processes that have led to the re-organisation of stroke care in the Czech Republic since 2011, which has been part of a broader process of care concentration in several medical fields. Currently, stroke care is provided by 13 Comprehensive and 32 Primary Stroke Centres. The paper explains factors that supported the reform implementation, reviews implications, and discusses future challenges.Mandatory reporting of quality indicators, the introduction of a benchmarking system, integration with pre-hospital emergency care, and the introduction of countrywide patient triage have supported more timely treatment for stroke patients and better quality of care. Data from the Stroke Care Quality Indicators of the Czech Stroke Society show positive trends in many areas: the number of patients treated with intravenous thrombolysis quadrupled in eight years, with 26.4 % of all acute stroke patients receiving thrombolysis in 2018. Czech Republic now ranks third in Europe in the number of thrombolysis per population and second in the number of mechanical thrombectomies per population. The Czech experience provides an example of positive outcomes of concentrated stroke care, while highlighting the importance of proper implementation processes. In particular, it is essential to involve stakeholders and to provide reputational incentives through continuous benchmarking.